購物車 
-
EIDD-2801
- names：
EIDD 2801
- CAS號：
2349386-89-4
MDL Number： - MF(分子式)： C13H19N3O7 MW(分子量)： 329.1223
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| HCQ000014-5kg | 5kg | 98% | ￥ 0.00 | ￥ 0.00 | Get quote | ￥ 0.00 | ||
| HCQ000014-1kg | 1kg | 98% | ￥ 0.00 | ￥ 0.00 | Get quote | ￥ 0.00 | ||
| HCQ000014-1g | 1g | 98% | ￥ 32500.00 | ￥ 32500.00 | 19520 | Get quote | ￥ 0.00 | |
| HCQ000014-100mg | 100mg | 98% | ￥ 17800.00 | ￥ 17800.00 | 3180 | Instock | ￥ 0.00 | |
| HCQ000014-25mg | 25mg | 98% | ￥ 9800.00 | ￥ 9800.00 | 1850.00 | Instock | ￥ 0.00 | |
| HCQ000014-10mg | 10mg | 98% | ￥ 4950.00 | ￥ 4950.00 | 1050 | Instock | ￥ 0.00 |
| 中文別名 | EIDD-2801(cas:2349386-89-4),EIDD2801,EIDD 2801 |
| 英文別名 | 2349386-89-4,EIDD 2801,[(2R,3S,4R,5R)-3,4-dihydroxy-5-[(4Z)-4-(hydroxyimino)-2-oxo-1,2,3,4-tetrahydropyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate |
| CAS號 | 2349386-89-4 |
| Inchi | InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1 |
| InchiKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N |
| 分子式 Formula | C13H19N3O7 |
| 分子量 Molecular Weight | 329.1223 |
| 溶解度Solubility | |
| 性狀 | 固體粉末 |
| 儲藏條件 Storage conditions | Store at -4℃;干燥避光存儲，短期運輸時（-4℃）長期存儲-20℃。 |
| 產品說明 | EIDD-2801(CAS:2349386-89-4) is an orally bioavailable isopropylester cytidine analog being investigated to treat COVID-19. |
| Introduction | EIDD-2801 is the isopropylester prodrug of N4-hydroxycytidine.1,2 With improved oral bioavailability in non human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5’-triphosphate form.2 The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe.3 Recent studies have shown EIDD-2801 inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.1 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.1 |
| Application1 | 潛在冠狀病毒抑制劑Experimental Unapproved Treatments for COVID-19 |
| Application2 | EIDD-2801 is a potent broad-spectrum antiviral agent. It is a useful tool for newly emerging coronavirus infections of the future. |
| Application3 |
EIDD-2801在體內水解成為為N4-羥基胞苷，N4-羥胞苷在組織中被磷酸化為活性5'-三磷酸形式，并摻入新病毒體的基因組中，導致病毒失活突變的積累。
A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine
EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. It has broad-spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment.
EIDD-2801是核糖核苷類似物EIDD-1931的口服生物可利用的前藥。它具有針對流感病毒和多種冠狀病毒（如SARS-CoV-2，MERS-CoV，SARS-CoV）的廣譜抗病毒活性。 EIDD-2801具有抑制COVID-19以及季節性和大流行性流感病毒的潛在能力。
EIDD-2801 is the isopropylester prodrug of N4-hydroxycytidine.1,2 With improved oral bioavailability in non human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5’-triphosphate form.The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. Recent studies have shown EIDD-2801 inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.1 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.
In vivo：
50, 150, or 500 mg/kg EIDD-2801 orally administered in the intranasal infection mouse-adapted SARS-CoV (SARS-MA15). The body weight loss compared to vehicle treatment was significantly diminished (50 mg/kg) or prevented (150, 500 mg/kg) with EIDD-2801 prophylaxis. Therefore, EIDD-2801 is robustly antiviral and able to prevent SARS-CoV replication and disease. Altogether, therapeutic EIDD-2801 is potently antiviral against SARS-CoV in vivo but the degree of clinical benefit was dependent on the time of initiation postinfection.
| 警示圖 | |
| 危險性 | |
| 危險性警示 | Not Available |
| 安全聲明 | NA |
| 安全防護 | 實驗過程防止食如、吸入 |
| 備注 | NA |
| T. P. Sheahan et al.: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med.. 2.Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK: Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: 11/515/eaax5866. doi: 10.1126/scitranslmed.aax5866. [PubMed:31645453] |
| Hampton T: New Flu Antiviral Candidate May Thwart Drug Resistance. JAMA. 2020 Jan 7;323(1):17. doi: 10.1001/jama.2019.20225. [PubMed:31910262] |
| Sheahan TP, et al. Sci Transl Med. 2020 Apr 6. pii: eabb5883. |
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
